Drugs / TS-134
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05401227 | Oct 2022 → Aug 2028 expected | — | New York State Psychiatric Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT03141658 | Jun 2017 → Apr 2018 | — | Taisho Pharmaceutical R&D Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03742791 | Jun → Dec 2016 | — | Taisho Pharmaceutical R&D Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03746067 | Aug 2015 → Jan 2016 | — | Taisho Pharmaceutical R&D Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TS-134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03141658 ↗ |
| Route | Oral | “TS-134 Administered Orally” NCT03742791 ↗ |